NASDAQ
CTY
Last Price
US $22.4
Valuation
Financial
Performance
Cash flow to debt coverage
City Therapeutics Inc. cash flow to debt ratio of 55.99% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Free cash flow growth
City Therapeutics Inc.'s free cash flow has decreased 17.23% from $2.75B last year to $2.28B, signaling decreasing performance
Debt-to-equity ratio
City Therapeutics Inc. has insufficient data to evaluate this check.
Debt-to-equity trend
City Therapeutics Inc. has insufficient data to evaluate this check.
Net debt to EBITDA
City Therapeutics Inc. has a net debt to EBITDA ratio of 1.55x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Interest coverage
Interest expense is not separately reported in City Therapeutics Inc.'s latest filing, so interest coverage cannot be calculated.
Profit margin growth
City Therapeutics Inc.'s profit margin was 19.60% last year and is 22.40% this year, signaling increasing performance
Current ratio
City Therapeutics Inc. has insufficient data to evaluate this check.
Return on assets
City Therapeutics Inc.'s return on assets of 8.70% is higher than the 5.00% threshold, indicating efficient asset utilization
Return on equity
City Therapeutics Inc.'s return on equity of 18.28%, is higher than 15.00%, indicating good performance
Earnings quality
City Therapeutics Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Earnings stability
City Therapeutics Inc. has insufficient public price history to evaluate earnings stability.
Positive free cash flow
City Therapeutics Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
City Therapeutics Inc. has a free cash flow yield of 1.05K%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Earnings growth
City Therapeutics Inc.'s yearly earnings has increased 9.73% since last year from $1.67B to $1.83B, signaling increasing performance
Revenue growth
City Therapeutics Inc. has insufficient data to evaluate this check.
Return on invested capital
ROIC 11.42% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
3-year revenue CAGR
City Therapeutics Inc.'s 3-year revenue CAGR of -2.90% is negative, indicating declining revenue over the past 3 years
Revenue consistency
City Therapeutics Inc. has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
City Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.
Base Cash Flow Valuation (DCF)
City Therapeutics Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
City Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Base EBITDA Valuation
City Therapeutics Inc. has insufficient data to evaluate this check.
EV/EBITDA (FY)
City Therapeutics Inc. has an EV/EBITDA ratio of 1.61x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
PEG ratio (TTM/FY)
City Therapeutics Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.
Price-to-book ratio (FY)
City Therapeutics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
City Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $22.4
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.